Persistent androgen signaling is functionally significant in castration-resistant prostate cancer (CRPC) and it is actually considered a validated therapeutic target. Residual intra-tumoral androgens compensate for the effects of androgen ablation, activating the androgen receptor (AR), AR-mediated gene expression and driving CRPC. The intra-tumoral biosynthesis of androgens takes place in different ways and cytochrome P450 17A1 (CYP17A1) has a crucial role in this context. Abiraterone, a CYP17A1 inhibitor, has shown impressive results in pre- and post-chemotherapy settings, prolonging the survival of patients with CRPC. However, not all patients respond to the treatment and most responders develop resistance, with a widely variable duration of response. Although many hypotheses are emerging, the mechanisms of resistance to abiraterone treatment have not yet been elucidated. The aim of the present review is to describe the main data currently available on resistance to abiraterone.
Written by:
Giacinti S, Bassanelli M, Aschelter AM, Milano A, Roberto M, Marchetti P. Are you the author?
Department of Oncology, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy; Department of Medical and Surgical Sciences and Translational Medicine, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy.
Reference: Anticancer Res. 2014 Nov;34(11):6265-6269.
PubMed Abstract
PMID: 25368223
Go "Beyond the Abstract" - Read an article written by the authors for UroToday.com